ALKS up +3.18% percent Today $ALKS High is at 53.0
Post# of 97
Posted On: 11/10/2014 1:18:40 PM
ALKS up +3.18% percent Today $ALKS High is at 53.00 and the Low 50.41 with current volume of 417,540.
Recent News posted below.
Alkermes Plc ALKS other info.
http://investorshangout.com/Alkermes-ALKS-53277/
ALKS Alkermes Plc Recent Headline News
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - 2 hrs 7 mins ago
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 10.79 (-0.44), SGEN: 35.73 (-0.32), DNDN: 0.24 (-0.70), EXAS: 22.52 (-0.30), ALKS: 52.70 (+1.70)
Alkermes Up 15.8% Since SmarTrend Uptrend Call (ALKS)
Comtex SmarTrend(R) - Wed Nov 05, 9:32AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on October 21st, 2014 at $43.66. In approximately 2 weeks, Alkermes has returned 15.76% as of today's recent price of $50.54.
ALKS: 52.70 (+1.70)
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014, at 11:00 a.m. MST (1:00 p.m. EST/6:00 p.m. GMT) from Phoenix, Ariz. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.70 (+1.70)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 324.97 (+4.22), AZN: 73.19 (+0.31), ACOR: 35.75 (+0.64), ALKS: 52.70 (+1.70)
Alkermes reports 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
DUBLIN 4, Ireland (AP) _ Alkermes PLC (ALKS) on Wednesday reported a loss of $40 million in its third quarter.
ALKS: 52.70 (+1.70)
Alkermes plc Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:00AM CDT
---- Non-GAAP Diluted EPS of $0.03 for Third Quarter --
ALKS: 52.70 (+1.70)
Watch for Alkermes to Potentially Pullback After Gaining 1.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 5:35PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $43.38 to a high of $44.79. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $44.18 on volume of 703,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 52.70 (+1.70)
Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Oct 22, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Wednesday, Oct. 29, 2014, to discuss the company's financial results for the third quarter of 2014. Management will review the quarter and provide an update on the company.
ALKS: 52.70 (+1.70)
Alkermes' New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Business Wire - Wed Oct 22, 6:00AM CDT
---- FDA Action Expected by Aug. 22, 2015 --
ALKS: 52.70 (+1.70)
OTC Daily Alert Stock Watch - Alkermes Public Limited Company (NASDAQ: ALKS)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ALKS: 52.70 (+1.70)
Alcohol Addiction Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf3gh/alcohol) has announced the addition of the "Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Alkermes Plc - Duramed Pharmaceuticals, Inc. - Odyssey Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. - Forest Laboratories, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/grf3gh/alcohol
ALKS: 52.70 (+1.70), FRX: 99.00 (-0.77), VRX.TO: 145.13 (+2.29)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70), FRX: 99.00 (-0.77)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.20 (+0.04), ENZN: 1.11 (unch), AMRN: 0.84 (-0.06), ALKS: 52.70 (+1.70), ARRY: 3.90 (+0.02)
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
TSLA: 241.30 (+1.10), TMK: 53.05 (-0.41), AMZN: 303.51 (+3.65), FB: 74.85 (-0.75), EW: 123.54 (+0.78), GEL: 49.62 (+0.03), ALKS: 52.70 (+1.70), CELG: 107.63 (+1.18), YHOO: 49.07 (+0.52), SWI: 48.31 (unch), ANGI: 6.44 (-0.17), STJ: 65.15 (+0.39), DE: 88.66 (unch), JDSU: 13.62 (-0.01), GOOGL: 558.66 (+6.84), AIG: 54.09 (+0.06), ZNGA: 2.46 (+0.03), EPD: 37.91 (+0.29), FSIC: 10.45 (unch)
'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical
at The Street - Tue Sep 16, 5:00AM CDT
Cramer likes Alkermes, says hold on to Zynga but wants you to avoid SolarWinds.
TMK: 53.05 (-0.41), SWI: 48.31 (unch), STJ: 65.15 (+0.39), EW: 123.54 (+0.78), DE: 88.66 (unch), GEL: 49.62 (+0.03), AIG: 54.09 (+0.06), ZNGA: 2.46 (+0.03), ALKS: 52.70 (+1.70), EPD: 37.91 (+0.29)
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 36.76 (+0.57), CPRX: 2.68 (-0.05), ALKS: 52.70 (+1.70), ACUR: 0.60 (+0.02), OMER: 17.24 (-0.13)
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
GILD: 107.45 (+1.00), LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70), CELG: 107.63 (+1.18)
Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic
Business Wire - Wed Sep 03, 6:00AM CDT
--- Topline Data From 12-Week, Double-Blind Treatment Period Expected in Early 2015 -
ALKS: 52.70 (+1.70)
Alkermes' Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference
Business Wire - Tue Sep 02, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global Healthcare Conference on Monday, Sept. 8, 2014, at 11:05 a.m. EDT (4:05 p.m. BST) from the Grand Hyatt New York. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.70 (+1.70), MS: 35.70 (+0.04)
Recent News posted below.
Alkermes Plc ALKS other info.
http://investorshangout.com/Alkermes-ALKS-53277/
ALKS Alkermes Plc Recent Headline News
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - 2 hrs 7 mins ago
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 10.79 (-0.44), SGEN: 35.73 (-0.32), DNDN: 0.24 (-0.70), EXAS: 22.52 (-0.30), ALKS: 52.70 (+1.70)
Alkermes Up 15.8% Since SmarTrend Uptrend Call (ALKS)
Comtex SmarTrend(R) - Wed Nov 05, 9:32AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on October 21st, 2014 at $43.66. In approximately 2 weeks, Alkermes has returned 15.76% as of today's recent price of $50.54.
ALKS: 52.70 (+1.70)
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014, at 11:00 a.m. MST (1:00 p.m. EST/6:00 p.m. GMT) from Phoenix, Ariz. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.70 (+1.70)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 324.97 (+4.22), AZN: 73.19 (+0.31), ACOR: 35.75 (+0.64), ALKS: 52.70 (+1.70)
Alkermes reports 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
DUBLIN 4, Ireland (AP) _ Alkermes PLC (ALKS) on Wednesday reported a loss of $40 million in its third quarter.
ALKS: 52.70 (+1.70)
Alkermes plc Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:00AM CDT
---- Non-GAAP Diluted EPS of $0.03 for Third Quarter --
ALKS: 52.70 (+1.70)
Watch for Alkermes to Potentially Pullback After Gaining 1.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 5:35PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $43.38 to a high of $44.79. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $44.18 on volume of 703,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 52.70 (+1.70)
Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Oct 22, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Wednesday, Oct. 29, 2014, to discuss the company's financial results for the third quarter of 2014. Management will review the quarter and provide an update on the company.
ALKS: 52.70 (+1.70)
Alkermes' New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Business Wire - Wed Oct 22, 6:00AM CDT
---- FDA Action Expected by Aug. 22, 2015 --
ALKS: 52.70 (+1.70)
OTC Daily Alert Stock Watch - Alkermes Public Limited Company (NASDAQ: ALKS)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ALKS: 52.70 (+1.70)
Alcohol Addiction Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf3gh/alcohol) has announced the addition of the "Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Alcohol Addiction- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Alkermes Plc - Duramed Pharmaceuticals, Inc. - Odyssey Pharmaceuticals, Inc. - Teva Pharmaceuticals USA, Inc. - Forest Laboratories, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/grf3gh/alcohol
ALKS: 52.70 (+1.70), FRX: 99.00 (-0.77), VRX.TO: 145.13 (+2.29)
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vx7ff/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023" report to their offering. Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023 This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, says a new report from research and consulting firm The authors. According to the company's latest report*, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%. However, The authors forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR. The authors states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck's brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma's cariprazine, Alkermes's ALKS-5461 and Naurex's GLYX-13, along with antidepressant therapies, including Euthymics Bioscience's amitifadine, Lundbeck/Takeda's tedatioxetine and e-Therapeutics' ETS6103. Koutsokeras continues: All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. With their ability to address some of the MDD treatment market's key unmet needs, we believe that these products' launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda's Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Epidemiology - Risk Factors and Comorbidities - Global and Historical Trends - Forecast Methodology - Epidemiological Forecast for MDD (2013-2023) 5 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 6 Competitive Assessment - Lexapro (Escitalopram) - Viibryd (Vilazodone) - Other Selective Serotonin Reuptake Inhibitors - Effexor (Venlafaxine) - Cymbalta (Duloxetine) - Pristiq (Desvenlafaxine) - Fetzima (Levomilnacipran) - Savella (Milnacipran) - Norepinephrine-Dopamine Reuptake Inhibitors - Noradrenaline and Specific Serotonergic Antidepressants - Monoamine Oxidase Inhibitors - Tricyclic Antidepressants - Brintellix (Vortioxetine) - Abilify (Aripiprazole) - Seroquel XR (Quetiapine) 7 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 8 Pipeline Assessment - Brexpiprazole (OPC-34712) - Cariprazine (RGH-188) - ALKS-5461 - Amitifadine (EB-1010) - GLYX-13 - Tedatioxetine (Lu AA24530) - ETS6103 - Other Drugs in Development 9 Current and Future Players - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics 10 Market Outlook - Global - US - France - Germany - Italy - Spain - UK - Japan - Australia 11 Appendix For more information visit http://www.researchandmarkets.com/research/9v...harmapoint
LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70), FRX: 99.00 (-0.77)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.20 (+0.04), ENZN: 1.11 (unch), AMRN: 0.84 (-0.06), ALKS: 52.70 (+1.70), ARRY: 3.90 (+0.02)
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
TSLA: 241.30 (+1.10), TMK: 53.05 (-0.41), AMZN: 303.51 (+3.65), FB: 74.85 (-0.75), EW: 123.54 (+0.78), GEL: 49.62 (+0.03), ALKS: 52.70 (+1.70), CELG: 107.63 (+1.18), YHOO: 49.07 (+0.52), SWI: 48.31 (unch), ANGI: 6.44 (-0.17), STJ: 65.15 (+0.39), DE: 88.66 (unch), JDSU: 13.62 (-0.01), GOOGL: 558.66 (+6.84), AIG: 54.09 (+0.06), ZNGA: 2.46 (+0.03), EPD: 37.91 (+0.29), FSIC: 10.45 (unch)
'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical
at The Street - Tue Sep 16, 5:00AM CDT
Cramer likes Alkermes, says hold on to Zynga but wants you to avoid SolarWinds.
TMK: 53.05 (-0.41), SWI: 48.31 (unch), STJ: 65.15 (+0.39), EW: 123.54 (+0.78), DE: 88.66 (unch), GEL: 49.62 (+0.03), AIG: 54.09 (+0.06), ZNGA: 2.46 (+0.03), ALKS: 52.70 (+1.70), EPD: 37.91 (+0.29)
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 36.76 (+0.57), CPRX: 2.68 (-0.05), ALKS: 52.70 (+1.70), ACUR: 0.60 (+0.02), OMER: 17.24 (-0.13)
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
GILD: 107.45 (+1.00), LLY: 67.82 (+1.22), ALKS: 52.70 (+1.70), CELG: 107.63 (+1.18)
Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic
Business Wire - Wed Sep 03, 6:00AM CDT
--- Topline Data From 12-Week, Double-Blind Treatment Period Expected in Early 2015 -
ALKS: 52.70 (+1.70)
Alkermes' Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference
Business Wire - Tue Sep 02, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global Healthcare Conference on Monday, Sept. 8, 2014, at 11:05 a.m. EDT (4:05 p.m. BST) from the Grand Hyatt New York. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.70 (+1.70), MS: 35.70 (+0.04)
(0)
(0)Alkermes plc (ALKS) Stock Research Links
Scroll down for more posts ▼